Calendario›TRAW›ON 01910.Na Concentrate

ON 01910.Na Concentrate

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Ensayo de Traws Pharma, Inc. en Sindromes mielodisplasicos.

Más ensayos de: Síndromes mielodisplásicos.

Fase

Fase 1/2

Estado

Retirado antes de empezar

Centros

1

Fin del objetivo primario

jun 2010

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en mar 2009.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Mutual decision by site and sponsor because of difficulty recruiting Patients.».

Qué mide

Maximum tolerated dose (in Phase 1) (del registro, en inglés) (1 mes)

Cómo lo describe el promotor

En el documentoEn inglés, del registroFor MDS patients who have not responded to or have progressed after an initial response to DNA methyltransferase inhibitors (DNMTI) and are not stem cell transplant candidates, therapeutic options are limited. Participation in clinical trials such as this one may be considered. The specific objectives of this trial are to find out which dose of ON 01910.Na can be safety given to MDS patients and then find out if this dose of drug has any beneficial effects on the patients' disease. ON 01910.Na is a new, experimental drug; the reason for doing this trial is based on the anti-cancer activity of ON 01910.Na that has been observed in laboratory experiments and in early clinical trials.

Más ensayos de TRAW

Todos los de TRAW, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00867061), actualizada en jun 2017.